Document is current
Any future updates will be listed below
-
Authors
Khan, Sajid http://orcid.org/0000-0003-1331-8846
Wiegand, Janet
Zhang, Peiyi
Hu, Wanyi
Thummuri, Dinesh
Budamagunta, Vivekananda
Hua, Nan
Jin, Lingtao
Allegra, Carmen J.
Kopetz, Scott E.
Zajac-Kaye, Maria
Kaye, Frederic J.
Zheng, Guangrong
Zhou, Daohong
-
Funding
Funding for this research was provided by:
National Cancer Institute (R01 CA242003)
- License Information
-
More Information
Article History
Received: 5 January 2022
Accepted: 19 February 2022
First Online: 9 March 2022
Declarations
:
: All the animal procedures were performed in accordance with the rules of the IACUC at the University of Florida.
: Not applicable.
: S.K., P.Z., D.T., G.Z. and D.Z. are inventors of two patent applications for use of BCL-X<sub>L</sub> PROTACs as senolytic and antitumor agents. G.Z. and D.Z. are co-founders of and have equity in Dialectic Therapeutics, which develops BCL-X<sub>L</sub>/2 PROTACs to treat cancer.
